<DOC>
	<DOC>NCT00802919</DOC>
	<brief_summary>This is a 12-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with schizophrenia. Correlations will be made with biological predictors of efficacy: a) measures of nicotinic receptors in lymphocytes b) DNMT1 and GAD67 mRNA in lymphocytes. Subjects will be current cigarette smokers or hsitory of regular smokers.</brief_summary>
	<brief_title>Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Diagnosis of Schizophrenia or Schizoaffective Disorder Current Cigarette Smoker Age 1865 Currently taking antipsychotic medication prior history of hospitalization for acute myocardial infarction or stroke, or persistent angina pectoris with current symptoms Patients who have previously tried varenicline and have stopped taking it because of sideeffects of severe nausea or vomiting suicide attempt in the last year and or have had prominent or serious suicidal thoughts in the past year Women who are pregnant, nursing, or unable to use reliable contraception significant renal impairment(Creatinine â‰¥ 1.5) baseline Hamilton Depression Scores is &gt;20</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>smoking</keyword>
	<keyword>nicotine</keyword>
	<keyword>cognitive deficits</keyword>
	<keyword>DNMT1 mRNA</keyword>
	<keyword>nicotinic receptors</keyword>
	<keyword>Cognitive Deficits in Schizophrenia</keyword>
</DOC>